Topical minoxidil is available over-the-counter (OTC) and as such is widely used for the treatment of hair loss; however, following 4-6 months of daily or twice daily application, a significant number of patients do not respond to the drug.  Since hair loss is progressive and is often a manifestation of an underlying condition other than pattern hair loss, identifying patients that are unlikely to respond to topical minoxidil is of great importance.

The Minoxidil Response Test was developed to aid a physician in assessing if a patient is likely not to respond to topical minoxidil treatment for pattern hair loss.

At the Daniel Alain Life Science, we are developing new medical devices and drugs for the treatment of male and female pattern hair loss.  In September 2017, our parent company, Follea International Ltd., submitted a De Novo application for a medical device – the Minoxidil Response test.